Microbot Medical

Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The firm carries out its operations through the ViRob and TipCat platforms. The ViRob platform technology is an autonomous crawling micro-robot that can be controlled remotely or within the body. It makes use of the Self-Cleaning Shunt, a robotic system designed as the ventricular catheter portion of a Cerebrospinal Fluid shunt system and is mainly used for the treatment of hydrocephalus and Normal Pressure Hydrocephalus. The TipCat platform, a self-propelling, flexible, and semi-disposable endoscope, provides see-and-treat capabilities within tubular lumens in the human body such as the colon, blood vessels, and the urinary tract. The company was founded by Harel Gadot, Moshe Shoham, and Yosseph Bornstein on August 2, 1988 and is headquartered in Hingham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies The presentation follows successful extensive uses of the Company's endovascular robotic system in pre-clinical studies

Microbot Medical Gains Global Recognition; Professor Vincent Vidal to Present an Abstract on The LIBERTY® Robotic Surgical System at CIRSE 2023

The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercialization The Agreement with a leading full turnkey manufacturer further strengthens the Company's progression towards expected first in human clinical trials followed by regulatory approval and commercialization

Microbot Medical Boosts Manufacturing and Commercialization Capabilities for its Robotic Surgical System

Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapies

Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board

Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union Engagement includes audit plans for ISO 13485 certification, to pave the way for obtaining CE Mark for clearance of sales in the European Union

Microbot Medical Engaging with a Leading Notified Body to Advance CE Mark for Sales in Europe

Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional Radiology Believes that the reduction in radiation exposure the LIBERTY® system could empower more women to pursue careers in Interventional Radiology

Microbot Medical Expands its Physician Support with the Addition of Leading Italian Interventional Radiologist Irene Bargellini, M.D., to its Scientific Advisory Board

HINGHAM, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it closed its previously announced registered direct offering for the purchase and sale of 624,618 shares of the Company's common stock at a purchase price of $3.25 per share of common stock priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered series D preferred investment options. The series D preferred investment options to purchase up to 312,309 shares of common stock have an exercise price of $3.19 per share and are immediately exercisable for a period of five and one-half years following issuance.

Microbot Medical Raises a Total of $7.6 Million in Gross Proceeds from Four Recent Registered Direct Offerings

Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic Drive Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic Drive

Microbot Medical Expand IP protection in Japan

Company Believes the Continuous Accumulation of Peer-Reviewed Data will Accelerate the Adoption of its Novel Interventional Endovascular System Once Commercialized Company Believes the Continuous Accumulation of Peer-Reviewed Data will Accelerate the Adoption of its Novel Interventional Endovascular System Once Commercialized

Microbot Medical Announces Multiple Peer Reviewed Abstracts Accepted by The Cardiovascular and Interventional Radiological Society of Europe

HINGHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 701,756 shares of the Company's common stock at a purchase price of $2.1375 per share of common stock priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company issued unregistered series C preferred investment options. The series C preferred investment options to purchase up to 350,878 shares of common stock have an exercise price of $2.075 per share and are immediately exercisable for a period of five and one-half years following issuance.

Microbot Medical Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company's common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series C preferred investment options. The series C preferred investment options to purchase up to 350,878 shares of common stock have an exercise price of $2.075 per share and are immediately exercisable for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about June 6, 2023, subject to the satisfaction of customary closing conditions.

Microbot Medical Announces $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic surgical system, announced it has received a grant from the Israel Innovation Authority ("IIA”) in the amount of NIS 1.62 million, which based on a recent exchange rate to the U.S. dollar, would be approximately $440,000, to further support the development of the Company's manufacturing process of its flagship robotic surgical system, the LIBERTY®.

Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System

The data collected from the usage and experience of the medical professionals in the formative study will be used to support the Company's anticipated milestones The data collected from the usage and experience of the medical professionals in the formative study will be used to support the Company's anticipated milestones

LIBERTY Robotic Surgical System Achieved Additional Milestone in its Path to First in Human and Regulatory Process

This Significant Achievement Represents Major Progression Toward Regulatory and Commercialization Paths Additional Sites in the U.S. Are Expected to Participate in the Trial HINGHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has successfully achieved another major milestone representing the next step toward the regulatory and commercial paths for the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system.

Lahey Hospital & Medical Center Agrees to become One of the U.S. Sites for the LIBERTY® Robotic System's First Human Trial

HINGHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company's common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules.

Microbot Medical Announces Closing of $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 1,209,500 shares of the Company's common stock (or common stock equivalents) at a purchase price of $2.20 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about May 25, 2023, subject to the satisfaction of customary closing conditions.

Microbot Medical Announces $2.66 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Eos Energy Enterprises

EVgo

The stock market can provide investors with an unpredictable and thrilling journey, filled with both excitement and anticipation. This article will delve into the peak of that exhilaration – penny stocks, and particularly high return penny stocks which may be undervalued relative to their future potential.

3 Undervalued Penny Stocks to Buy for Multi-Bagger Returns

HINGHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 655,569 shares of the Company's common stock at a purchase price of $2.20 per share of common stock priced at-the-market under Nasdaq rules.

Microbot Medical Announces Closing of $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Microbot Medical Inc. NASDAQ: MBOT stock spiked more than 150% on a massive 194 million share volume on a successful pre-clinical animal study for its LIBERTY surgical robotic system. Shares hit a high of $4.37 intraday before closing at $3.19 on May 22, 2023.

Microbot Medical spikes 150% on its Endovascular Surgical Robot

AvroBio Inc

FuelCell Energy

Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.

How to Handle Penny Stocks Volatility in 2023

Celularity

Lucy Scientific Discovery Inc

Nordic American Tankers

I'm sure if you're on this site, you're looking for info on the best penny stocks today. That means researching trends, analyzing data, and reading up on the latest news to formulate a thesis.

Best Penny Stocks Today? 4 With Big News To Watch This Week

HINGHAM, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 655,569 shares of the Company's common stock at a purchase price of $2.20 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about May 24, 2023, subject to the satisfaction of customary closing conditions.

Microbot Medical Announces $1.4 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

A team of six leading European interventional radiologists used the LIBERTY® Surgical Robotic System and performed a total of 48 catheterizations A team of six leading European interventional radiologists used the LIBERTY® Surgical Robotic System and performed a total of 48 catheterizations

Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians

Company will enable focus on its LIBERTY technology through the introduction of the Core Business Focus Program coupled with cost restructuring to support it Company will enable focus on its LIBERTY technology through the introduction of the Core Business Focus Program coupled with cost restructuring to support it

Microbot Medical to Enhance Focus on its Core Business and Prioritize Preparations for Regulatory and First in Human Clinical Cases

Distinguished publisher and lecturer, Interventional Radiologist Prof. Francisco Cesar Carnevale Expected to Perform the World's First Clinical Cases at the Prestigious Institute of Radiology at the University of Sao Paulo Medical School Hospital Distinguished publisher and lecturer, Interventional Radiologist Prof. Francisco Cesar Carnevale Expected to Perform the World's First Clinical Cases at the Prestigious Institute of Radiology at the University of Sao Paulo Medical School Hospital

Microbot Medical Initiates Preparations for First-In-Human (FIH) Cases in Brazil for the LIBERTY® Robotic System

HINGHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic System, the first single-use endovascular robotic system, has received the histopathology report from the European-based MedTech research laboratory that performed the animal study for the LIBERTY Robotic System in October 2022.

News for Microbot Medical Stock (MBOT)